Eli Lilly, research group partner to increase diversity in oncology clinical trials

Eli Lilly plans to broaden patient access to clinical trials while expanding representation of minority group members by partnering with Care Access, a decentralized research organization. 
The partnership comes as a part of Lilly’s phase 3 clinical trial evaluating the safety of abemaciclib in high risk, early stage breast cancer patients taking hormone therapy after surgery. 
Care Access plans to increase diversity by creating partnerships with underrepresented surgical and medical oncologists, establishing community-based partnerships and educating patients on participation in trials based on medical needs. 
The study aims to collect data more representative of the U.S. population.

"This is critical for an illness like breast cancer in which women of color have been historically underrepresented in clinical trials," Amy Davis, senior director of oncology clinical development at Eli Lilly, said in a press release. "Our work with Care Access — an organization equally committed to increasing representation of minority group members in clinical trials — brings us one step closer to achieving these diversity goals.”


Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars